Stocks in Action USA: Harrow, Sarepta Therapeutics, and Elbit Systems.
Reading Time: 3 minutes
Harrow (HROW) – the MedTech company surprises with strong quarterly results – stock soaring! The stock of eye medication manufacturer Harrow saw a significant increase after the company announced much better preliminary results for the fourth quarter than expected. Harrow forecasts revenues between $65 and $67 million, significantly exceeding analyst expectations of $58.4 million. The net profit is expected to be between $5 and $7 million – a surprisingly positive outcome, as experts originally anticipated a loss of $300,000. For the year...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
